Work

Palbociclib Update

Year: 2023
Type: article
Abstract: PC is a strong and selective inhibitor of CDK4 and -6 that has a lot of effect in BC models. When used in conjunction with letrozole, it has been demonstrated to dramatically increase progression-free survival in the treatment of advanced breast cancer that contains an estrogen receptor. Therefore, we assessed the mechanism, pharmacokinetics, dose, method, administration, and patient acceptability of PC in this review paper.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7217907736
FWCI:
Cites: 14
Cited by:
Related to: 10